Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Group 1 - The controlling shareholder, Chengdu Enwei Investment (Group) Co., Ltd., has partially lifted the pledge on its shares in Enwei Pharmaceutical Co., Ltd., holding 25,733,200 shares, which accounts for 25.01% of the total share capital [2] - As of the announcement date, the total pledged shares by the shareholder and its concerted parties exceed 50% of their holdings, with 28,080,836 shares maturing in the next six months, representing 41.85% of their holdings and 27.29% of the total share capital, with a corresponding financing balance of 30 million yuan [2] - The shareholder and its concerted parties have a total of 47,420,836 shares maturing within one year, which is 70.67% of their holdings and 46.09% of the total share capital, with a financing balance of 48.9 million yuan [2] Group 2 - The shareholder and its concerted parties do not have any non-operating fund occupation or illegal guarantees that would harm the interests of the listed company [3] - The share pledge does not impact the company's operations, governance, or financial stability, and there are no obligations for major asset restructuring or performance compensation [3] - The financial status of the shareholder is good, and there is no risk of forced liquidation or transfer of pledged shares [4]

Group 1 - The controlling shareholder Chengdu Enwei Investment (Group) Co., Ltd. has released a pledge of 3 million shares, accounting for 11.66% of its holdings and 2.92% of the company's total share capital [1] - After this release, the total number of pledged shares by Enwei Group is 22.38 million, which represents 86.97% of its holdings and 21.75% of the total share capital [1] - The pledge was initiated on August 18, 2025, and the release date is February 4, 2026, with the pledgee being Xu Yingzhuang [1]

证券代码：301331 证券简称：恩威医药 公告编号：2026-005 恩威医药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"、"本公司"）近日接到控股股 东成都恩威投资（集团）有限公司（以下简称"恩威集团"）函告，获悉恩威集 团所持本公司的部分股份被办理了解除质押。恩威集团为公司控股股东，持有公 司 25,733,200 股，占公司总股本的 25.01%。具体事项如下： 2、股东股份累计质押情况 1 股东 名称 是否为控股股东 或第一大股东及 其一致行动人 本次解除 质押数量 （股） 占其所 持股份 比例 占公司 总股本 比例 质押 起始 日 质押 解除 日 质权人 质押 用途 恩威 集团 是 3,000,000 11.66% 2.92% 2025 /8/18 2026 /2/4 徐英壮 自身 生产 经营 合计 - 3,000,000 - 2.92% - - - - 1、本次股东股份解除质押基本情况 截至公告披露日，上述股东及其一致行动人所持质 ...

Summary of Key Points Core Viewpoint The article discusses the share transfer process of Enwei Pharmaceutical Co., Ltd. (恩威医药) through a price inquiry method, detailing the procedures, pricing, and compliance with regulatory requirements. Group 1: Inquiry Transfer Overview - The inquiry transfer involves the transfer of 4,000,000 shares, representing 3.89% of the company's total share capital, with a transfer price set at 26.54 yuan per share, totaling 106,160,000 yuan [10][20][22]. - The transfer was conducted by CITIC Securities, which acted as the organizing broker for the inquiry transfer [1][21]. Group 2: Pricing and Allocation Principles - The price floor for the inquiry transfer was determined to be no less than 70% of the average trading price of Enwei Pharmaceutical shares over the 20 trading days prior to January 26, 2026 [3][27]. - The allocation of shares was based on a priority system that favored higher subscription prices, followed by subscription quantities and the order of receipt of subscription forms [4][5]. Group 3: Compliance and Regulatory Adherence - The inquiry transfer process was confirmed to be legal and compliant with various regulations, including the Company Law and Securities Law of the People's Republic of China [11][17]. - CITIC Securities conducted a thorough qualification review of both the transferor and transferee, ensuring that all parties met the necessary criteria for participation in the inquiry transfer [14][15]. Group 4: Investor Participation - A total of 451 institutional investors received the subscription invitation, including 80 fund companies, 54 securities firms, and 250 private fund managers [7][28]. - The inquiry transfer received 32 valid subscription forms during the designated period, indicating strong interest from institutional investors [8][28]. Group 5: Conclusion and Future Implications - The transfer will not change the controlling shareholder or the actual controller of Enwei Pharmaceutical, ensuring stability in the company's governance structure [20][32]. - The shares acquired through this inquiry transfer are subject to a six-month lock-up period, preventing immediate resale by the investors [20][32].

Core Viewpoint - Chengdu Enwei Investment (Group) Co., Ltd. and its acting-in-concert parties have reduced their shareholding in Enwei Pharmaceutical Co., Ltd. from 69.10% to 65.22% through a non-public transfer of 4,000,000 shares at a price of 26.54 yuan per share, totaling 106,160,000 yuan, without affecting the company's control structure or governance [3][4][9]. Group 1 - The equity change involves Chengdu Enwei Investment (Group) Co., Ltd. and its acting-in-concert parties, which collectively held over 5% of Enwei Pharmaceutical's shares. The shareholding ratio decreased from 69.10% to 65.22% after the transfer [3][9]. - The transfer method was a non-public inquiry transfer, and it did not trigger a mandatory tender offer. The shares acquired through this transfer cannot be transferred for six months [3][4][15]. - The total number of shares transferred was 4,000,000, representing 3.89% of the company's total share capital, with a transaction price of 26.54 yuan per share [4][12]. Group 2 - The inquiry transfer was organized by CITIC Securities, which confirmed that the process adhered to relevant regulations and was conducted fairly and transparently [14][32]. - A total of 451 institutional investors received the subscription invitation, and 32 valid subscription bids were received during the designated time [22][24]. - The final allocation resulted in 11 institutional investors receiving shares, confirming the transfer price and quantity as per the established rules [25][26].

证券代码：301331 证券简称：恩威医药 公告编号：2026-004 恩威医药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东 权益变动触及 1%整数倍的提示性公告 股东成都恩威投资（集团）有限公司、成都杰威企业管理有限公司、成都瑞进恒企 业管理有限公司、成都泽洪企业管理有限公司、昌都市杰威特企业管理有限公司保证向 本公司提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、 准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 1、本次权益变动主体为成都恩威投资（集团）有限公司（以下简称"出让方"） 及一致行动人成都杰威企业管理有限公司、成都瑞进恒企业管理有限公司、成都 泽洪企业管理有限公司、昌都市杰威特企业管理有限公司，合计持有恩威医药股 份有限公司（以下简称"恩威医药"或"公司"）5%以上股份。本次权益变动方式为 股份减少（询价转让），本次权益变动后，出让方及一致行动人拥有权益的股份 占公司总股本的比例由 69.10%下降至 65.22%，占剔除公司回购专用账户股份后 总股本的比例由 69.82%下降至 65.8 ...

中信证券股份有限公司 关于恩威医药股份有限公司 股东向特定机构投资者询价转让股份的核查报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券"或"组织券商"）受委托担 任成都恩威投资（集团）有限公司（以下简称"出让方"）以向特定机构投资者 询价转让（以下简称"询价转让"）方式减持所持有的恩威医药股份有限公司（以 下简称"公司"或"恩威医药"）首次公开发行前已发行股份的组织券商。 经核查，中信证券就本次询价转让的股东、出让方是否符合《深圳证券交易 所上市公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转让 股份（2025 年修订）》（以下简称"《询价转让和配售指引》"）要求，本次询价转 让的询价、转让过程与结果是否公平、公正，是否符合《询价转让和配售指引》 的规定作出如下报告说明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2026 年 1 月 26 日，出让方所持公司首发前股份的数量及占公司总股本 比例情况如下： | 序 | 股东名称 | 持股数量（股） | 占公司总股本 | 占剔除公司已回购股份 | | --- | --- | --- | --- | --- | | 号 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Core Viewpoint - The company, Enwei Pharmaceutical Co., Ltd., has announced a preliminary pricing for a share transfer through an inquiry process, with a determined price of 26.54 yuan per share [3]. Group 1: Share Transfer Details - The preliminary transfer price is set at 26.54 yuan per share based on inquiries conducted on January 27, 2026 [3][4]. - A total of 30 institutional investors participated in the inquiry, including fund management companies, securities firms, insurance companies, private fund managers, and qualified foreign investors, with a total effective subscription of 16,476,000 shares, resulting in a subscription multiple of 4.12 times [4]. - The shares to be transferred have been fully subscribed, with the preliminary designated buyers being 11 institutional investors, intending to acquire a total of 4,000,000 shares [4]. Group 2: Transfer Mechanism - The share transfer will not be conducted through centralized bidding or block trading, and it does not involve a reduction in holdings through the secondary market [3]. - The shares acquired through this inquiry transfer cannot be transferred by the buyers within six months after the acquisition [3]. Group 3: Governance and Control - The share transfer does not involve any change in the company's control and will not affect the company's governance structure or ongoing operations [6].